{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:13:21Z","timestamp":1788786801746,"version":"build-2803163510"},"reference-count":25,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Introduction: Chemotherapy-induced thrombocytopenia (CIT) is a common dose-limiting toxicity that disrupts on-time, full-dose chemotherapy, yet no pharmacologic therapy is formally approved. Growing evidence from randomized and late-phase studies with thrombopoietin receptor agonists (TPO-RAs) has renewed interest in targeted supportive care. We evaluated the effectiveness and safety of eltrombopag for CIT in routine clinical practice. Methods: We conducted a small, retrospective, single-arm multicenter cohort study of 31 adults with solid tumors (74.2% stage IV). Given the descriptive, hypothesis-generating nature of this study, no causal inference regarding efficacy can be drawn. Platelet counts and chemotherapy continuity were tracked from baseline through week 12 after eltrombopag initiation. Bleeding, thrombosis, and laboratory safety signals were recorded. Results: The median platelet count increased from 33 \u00d7 109\/L at baseline to 71 \u00d7 109\/L at week 1 and 99.5 \u00d7 109\/L by week 12. Overall, 18\/31 patients (58.1%) resumed chemotherapy within 3 weeks, and 15\/31 (48.4%) completed planned regimens by week 6. Adverse events were limited to mild, transient elevations in transaminases (n = 3); no major bleeding or thrombotic events occurred. Conclusions: In this real-world multicenter cohort, eltrombopag was associated with rapid platelet recovery and improved chemotherapy deliverability with an acceptable safety profile. The retrospective, single-arm design and the hypothesis-generating nature of these findings preclude definitive conclusions regarding causal efficacy. These observational data highlight the need for prospective controlled trials to characterize the clinical role, optimal dosing, and long-term safety of oral TPO-RAs in CIT.<\/jats:p>","DOI":"10.3390\/hematolrep18030039","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:59:31Z","timestamp":1781146771000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eltrombopag for Chemotherapy-Induced Thrombocytopenia: A Multicenter Retrospective Real-World Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-4623","authenticated-orcid":false,"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Tekirdag Nam\u0131k Kemal University, 59030 Tekirdag, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3947-0355","authenticated-orcid":false,"given":"Fatos Dilan","family":"K\u00f6seo\u011flu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, \u0130zmir Bakircay University, 35665 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-9620","authenticated-orcid":false,"given":"Sevil","family":"Sadri","sequence":"additional","affiliation":[{"name":"Hematology Clinic, Bursa City Hospital, 16110 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-6514","authenticated-orcid":false,"given":"\u00dcnal","family":"Ata\u015f","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Akdeniz University, 07070 Antalya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6923-1470","authenticated-orcid":false,"given":"Ufuk","family":"Demirci","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Manisa Celal Bayar University, 45140 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-8531","authenticated-orcid":false,"given":"Rafiye","family":"\u00c7ift\u00e7iler","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Sel\u00e7uk University, 42131 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Akp\u0131nar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Tekirdag Nam\u0131k Kemal University, 59030 Tekirdag, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-3000","authenticated-orcid":false,"given":"Elif G\u00fcls\u00fcm","family":"\u00dcmit","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Trakya University, 22030 Edirne, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: Guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Soff","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jiang, L., Zhu, J., Chen, X., Wang, Y., Wu, L., Wan, G., Han, Y., Leng, X., Zhang, J., and Peng, L. (2024). Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12724-6"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, Cost, and Outcomes of Bleeding and Chemotherapy Dose Modification Among Solid Tumor Patients with Chemotherapy-Induced Thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15347354231168368","DOI":"10.1177\/15347354231168368","article-title":"Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients with Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment","volume":"22","author":"Wonders","year":"2023","journal-title":"Integr. Cancer Ther."},{"key":"ref_7","first-page":"925","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dld.2024.05.014","article-title":"Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer","volume":"57","author":"Hoba","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet Transfusion for Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"Liebman","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4274\/tjh.galenos.2024.2024.0055","article-title":"Management of Adult Primary Immune Thrombocytopenia: Delphi- Based Consensus Recommendations","volume":"41","author":"Demir","year":"2024","journal-title":"Turk. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Parnes","year":"2020","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e12701","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use","volume":"6","author":"Wilkins","year":"2022","journal-title":"Res. Pr. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","first-page":"1217","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/cncr.35292","article-title":"A real-world observation on thrombopoietic agents for patients with cancer treatment\u2013induced thrombocytopenia in China: A multicenter, cross-sectional study","volume":"130","author":"Chen","year":"2024","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102980","DOI":"10.1016\/j.rpth.2025.102980","article-title":"Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?","volume":"9","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Peshin, S., Dharia, A., Takrori, E., Kaur, J., Thanikachalam, K., and Iyer, R. (2025). Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment. Curr. Oncol., 32.","DOI":"10.20944\/preprints202507.2232.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: A randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: A randomized phase I study","volume":"4","author":"Winer","year":"2014","journal-title":"Cancer Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: An international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Safina","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00030-8","article-title":"Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia","volume":"9","author":"Lozano","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17588359241260985","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled, phase II study","volume":"16","author":"Qin","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yang, H., Xu, X., Tan, M., Gao, J., Fang, R., Liu, X., Chen, Z., Chen, L., Ruan, Y., and Xu, Y. (2025). Efficacy and safety of different treatments in chemotherapy-induced thrombocytopenia: A systematic review and network meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1549214"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:11:11Z","timestamp":1781151071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["hematolrep18030039"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18030039","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}